iGuard

iGuard is a Hong Kong-based biotechnology company specializing in the development of AI-driven RNA-based antiviral therapeutics. Spun off from the University of Hong Kong, the company utilizes a proprietary platform to design small interfering RNA (siRNA) molecules that target highly conserved regions of viral genomes, aiming to create treatments that are resilient against mutations. Their lead programs focus on respiratory viruses such as SARS-CoV-2 and Influenza, as well as chronic infections like Hepatitis B. By integrating artificial intelligence with deep virological expertise, iGuard seeks to accelerate the discovery of broad-spectrum antivirals for both current and future pandemic threats. The company is currently in the pre-clinical stage, working towards advancing its lead candidate, IG-101, into clinical trials.